LinkedIn
CCHO – Access to Medicine

Real World Evidence

Leveraging decades of expertise, we offer solutions for real-world data (RWD) analytics and real-world evidence (RWE) generation to meet diverse client needs across the pharmaceutical product development continuum.

Combining regional health system and policy knowledge with technical and analytic skills to deliver high-impact RWE solutions.

Integratedevidence planningReal-worlddata analysisReal-worldevidence generationEvidence synthesisand evaluationRWEservices
RWE services
Integrated evidence planningReal-world data analysisReal-world evidence generationEvidence synthesis and evaluation

Integrated Evidence Planning (IEP)

CCHO’s holistic, dynamic, and proactive approach encompasses the entire product lifecycle, from clinical development to commercialization and post-marketing activities, integrating RWE and clinical evidence generation and utilization strategies to support your clinical and commercial objectives. We ensure seamless multi-disciplinary stakeholder engagement and coordination across all activities to provide alignment of global and regional strategies.

We take our clients on the RWE journey from initial evidence gap analysis and protocol design through study implementation and evidence dissemination, with the aim to establish and communicate the real-world value of their products.

1Evidence gap analysisWhere the value story needs proof
2Protocol designStudy, framework and data sources
3Study implementationSites, recruitment, data collection
4Evidence disseminationManuscripts, abstracts, posters
ResultReal-world value communicatedTo payers, HTAs and clinicians

Real-World Data (RWD) Analysis

Retrospective RWE studies utilize and analyze RWD collected from routine clinical practice or administrative sources to evaluate treatment outcomes, healthcare utilization patterns, and patient characteristics. In today’s world, harnessing the power of RWD has proved to be highly valuable in driving informed healthcare decisions, particularly in the setting of rare disease approvals and the support of expanded indications.

CCHO leverages a diverse range of RWD sources, including:

Electronic health records (EHRs)
Insurance billing and claims databases
Administrative and hospital databases
Established drug or disease registries
Patient-reported outcomes (PROs) and health surveys
Wearable devices and mobile health apps

Real-World Evidence (RWE) Generation

Our RWE generation services are designed to deliver robust insights into the effectiveness, safety, and value of healthcare products in real-world settings. CCHO guides you through every step of your RWE journey, starting by understanding your needs and objectives and designing the optimal study, to developing the protocol, establishing the analytical framework, identifying data sources, managing sites, patient recruitment, and data collection, and supporting your communications needs by developing manuscripts, abstracts, and posters.

We conduct various types of studies including:

  • Prospective drug / disease registries
  • Burden of illness
  • Patient-reported outcomes (PROs)
  • Treatment and population trends
  • Cost and healthcare resource utilization (HCRU) analysis

Evidence Synthesis and Evaluation

  • Systematic and targeted literature review
  • Network meta-analysis

Every project deserves a white-gloved bespoke approach.

Tell us about your objectives and we will design the study, strategy or programme around them.

Request a consultation